Cagrilintide for weight loss: what the trials actually show

What did @jleeactive actually say?

The creator describes cagrilintide as a "long-acting amylin analog" that activates amylin and calcitonin receptors to signal fullness and slow gastric emptying. They cite roughly "11 to 12% average body weight reduction" for cagrilintide alone over about 68 weeks, then say combining it with semaglutide pushed average weight loss into "the 20% range," which they describe as "approaching surgical-level outcomes." The mechanism framing, amylin as a pancreatic hormone released alongside insulin, is also part of the pitch.

To the creator's credit, they're not selling cagrilintide as a miracle drug. They frame it as investigational, which it is. That said, some of the numbers are presented with more confidence than the underlying data actually support, and the "surgical-level outcomes" comparison deserves scrutiny.

Does the science back this up?

Mostly, yes, with some important caveats. The 20% weight loss figure comes primarily from the REDEFINE 1 trial, a phase 3 study of cagrilintide 2.4 mg combined with semaglutide 2.4 mg (the combination drug now called CagriSema). Frias et al. (2023, The Lancet) reported mean weight reduction of approximately 15.6% at 32 weeks in a phase 2 dose-finding study, with higher-dose arms pushing toward 20%. The full 68-week phase 3 data from REDEFINE 1, presented at ADA 2024, showed around 22.7% weight reduction in the combination arm, which does approach bariatric surgery territory for some participants.

The solo cagrilintide figure is trickier. Enebo et al. (2021, The Lancet) reported up to 10.8% weight loss with cagrilintide 4.5 mg monotherapy over 26 weeks, not 68 weeks. The "11 to 12% over 68 weeks" framing conflates different trials and dosing durations. It's not wildly wrong, but it's not a clean citation either.

What did they get wrong (or right)?

The mechanism description is largely accurate. Amylin is co-secreted with insulin from pancreatic beta cells, and cagrilintide does act on amylin and calcitonin receptors. The concept of "dual pathway" weight loss by combining GLP-1 and amylin signaling is supported by the pharmacology. That part is solid.

Where the creator oversimplifies: the "surgical-level outcomes" comparison needs a lot of asterisks. Bariatric surgery produces 25 to 35% total body weight loss in many patients with durable results over years. CagriSema's 22.7% at 68 weeks is impressive, but it requires ongoing injections, and we have no long-term durability data past two years. The creator doesn't mention that cagrilintide is not approved anywhere, that CagriSema failed to hit its primary endpoint versus semaglutide alone in one secondary analysis reading, or that the nausea rates in trials were notably higher than semaglutide monotherapy. Saying side effects were "primarily nausea" undersells how common and discontinuation-relevant that was in the trials.

What should you actually know?

Cagrilintide is a legitimate investigational drug with real phase 3 data behind it. The dual-mechanism approach combining GLP-1 and amylin pathways has biological logic and clinical signal. But this drug is not approved by the FDA or EMA as of mid-2025. That means no legally compounded version can be considered equivalent to a future approved product, and any "research" sourcing should be understood for what it is.

The REDEFINE program results are genuinely interesting to follow. But 68-week data is not the same as 5-year outcome data, and we don't yet know what happens to weight when people stop taking it, what the cardiovascular endpoint data will show, or whether the nausea burden at therapeutic doses affects real-world adherence the way it has in trials. Anyone presenting this as a near-ready clinical tool is getting ahead of the evidence.